Novel Peptide Shows Promise for a Broad Spectrum of Inflammation-Related Disorders

“Therapies that are effective at symptom onset and provoke long-term resolution of subsequent relapses would be desirable for MS treatment,” Dr. Yuan and colleagues said. “In the preclinical animal model data presented here, our agents have performed satisfactorily in this regard.” The JM-4 peptide “shows promise for treatment of a broad spectrum of neural and non-neural conditions associated with inflammation,” concluded the researchers.

—Jake Remaly